Literature DB >> 7114002

Sustained-release theophylline for treatment of asthma in preschool children.

F E Simons, G H Luciuk, K J Simons.   

Abstract

Theo-Dur, a sustained-release theophylline formulation, was administered every 12 hours for three months to ten asthmatic children aged 3 to 7 years, with no evidence of adverse reaction or tolerance. There was significant temporal variation in serum theophylline concentrations. The mean difference between the peak and trough concentrations was 6.5 micrograms/mL (range, 3 to 14 micrograms/mL) in a 12-hour period. Serum theophylline concentrations correlated well with pulmonary function test results. Nine or more hours after a Theo-Dur dose, some children needed additional bronchodilator treatment and had impairment of pulmonary function. We recommend that children aged 7 years or younger who are given Theo-Dur have monitoring of predose serum theophylline concentrations, symptoms, and signs, as many will require a dose frequency greater than every 12 hours.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114002     DOI: 10.1001/archpedi.1982.03970450032008

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  7 in total

Review 1.  Theophylline.

Authors:  E F Ellis
Journal:  Clin Rev Allergy       Date:  1983-03

2.  Treatment of asthma in preschool children with slow release theophylline.

Authors:  B G Loftus; J F Price
Journal:  Arch Dis Child       Date:  1985-08       Impact factor: 3.791

3.  Comparison of the in vitro dissolution properties and in vivo steady-state pharmacokinetics of two sustained-release theophylline preparations.

Authors:  J H Jonkman; W J Van der Boon; G Grasmeijer
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

Review 4.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

5.  Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.

Authors:  J H Jonkman; W J van der Boon; L P Balant; R Schoenmaker; A Holtkamp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.

Authors:  J C Mucklow; S Kuhn
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

7.  Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

Authors:  M S Driscoll; T M Ludden; D T Casto; L C Littlefield
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.